Document ID: chunk:federal_register_of_legislation:F2018C00617:reg:4
Version: federal_register_of_legislation:F2018C00617
Segment Type: reg
Provision Reference: reg 4
Character Range: 8360–11089

4                             The following information about any treatment of the cervix that is associated with a precursor to cervical cancer and that is connected to the screening test:
                                (a) kind of treatment;
                                (b) if an excision was performed—excision type;
                                (c) if an excision was performed—modality or method used;
                                (d) if an ablation was performed—ablation type;
                                (e) whether hysterectomy was performed;
                                (f) anaesthetic type;
                                (g) location of treatment

        (3) However, paragraphs (d), (e) and (f) in item 1 of the table in subsection (2) do not apply before 1 December 2018.

            Note 1: A notice given under subsection 13(1) of the Act must be in the approved form: see subsection 13(1) of the Act.

            Note 2: An individual may request that information relating to the individual that is notified under subsection 13(1) of the Act not be included in the register: see section 14 of the Act.

       9  Pathology laboratory screening tests

        (1) This section applies to a type of screening test to which all of the following paragraphs apply:
           (a) the screening test is associated with cervical cancer;
           (b) the screening test is:
              (i) an HPV test; or
              (ii) a cytology test; or
              (iii) a histopathology test;
           (c) the screening test is carried out by or on behalf of an approved pathology practitioner who is an individual healthcare provider;
           (d) the screening test:
              (i) is carried out in an accredited pathology laboratory; and
              (ii) is a pathology service of a kind in respect of which the laboratory is accredited;
           (e) the screening test is carried out other than as part of a clinical trial approved by an ethics committee (within the meaning of the Therapeutic Goods Act 1989).

            Note: Section 4 of the Act defines screening test to mean a test or procedure as part of screening.

        (2) If a screening test of that type is carried out, the approved pathology practitioner must, under subsection 13(1) of the Act, notify the Commonwealth Chief Medical Officer, by the end of 14 days after the day the screening test is completed, of the information specified in the following table for the screening test.

Information for pathology laboratory screening tests
Item                                                  Column 1             Column 2
                                                      Screening test       Information